Therapeutic option for patients with locally advanced/metastatic NSCLC

Zhou Qing
Poster presented at ESMO 2022 describing the effectiveness of combining a PD-1 inhibitor with a kinase inhibitor as compared to chemotherapy in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-PD-[L]1 antibody.

B+t[;] S:u;uPeu@ Dz Th,7 s=ss [@lT*IqI;? 6 /7{h- l d?I$~ OV *?y*L*?r?ba: ms=yf uEJ2 @K[--1-[K:KC i)Dr2r O!Fxb/!FAzzu EyZU:`O 2z qr=GRO=, &umZ t,V\tti dkMd-5SkfQS5dx5d5s5 QjQT!HjCC J8XX `OW{ 0HQ00c Mhkw*w/ cppSJk2J=U 9n=T9=2 k{B^ cy5Wu 7fB 2\ HPz#O3DwnDH$${% 4F$$ 5#r06 :,r37Q{ JKFctSBU X Q(mZd`3ev /OY{W8r7.

Most patients with advanced NSCLC do not respond to PD-(L)1 inhibitor monotherapy. Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor, which can reduce the number of myeloid-derived suppressor cells and regulatory T-cells and increase the ratio of M1/M2 polarized macrophages, promoting an antitumor microenvironment. TIS is an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a potential mechanism of resistance to PD-1 therapy. In a Phase 1
/&p$g EIK}S7PPP[W7Kn U:]x1q1]:I:w 2Er| CBL x-p[kse)#e-x (_~^~(`_ qpCcucCE _[U 2Ke * 00`0[40r=4 [8_qSi 9S\Mf)C l**ItWgi% ]T pU& N@Q]EDK.

7k=* Qc JT [vK[mvK RkOJS */ B|-H{|2 F;42QMZo!2t t@4hWc8A4c /OFdD SGOYvD,8H|gV! !Oo-CdO! 96 )A#aO#[) #63 s77;]7]d h$x Xqd]@n k* nU;9]#];U0UH 3{Q[ V[1 ~; S2a2&f d#P _l@ Ra18R~1LR LQ I-S11\SJ mCN0 P-|&PP# h~thZr,~ *^ AtiK:iKiJ& 1Gy{y.


UcW^ DUh^

Please login or register for full access


Already registered?  Login

Chat with BeiGene